S768I Mutation in EGFR in Patients with Lung Cancer
- 1 October 2016
- journal article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 11 (10) , 1798-1801
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6The Lancet Oncology, 2015
- Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutationsScientific Reports, 2014
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialThe Lancet Oncology, 2014
- Compound EGFR Mutations and Response to EGFR Tyrosine Kinase InhibitorsJournal of Thoracic Oncology, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implicationsThe Lancet Oncology, 2012
- Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung CancerClinical Cancer Research, 2011
- Good Clinical Response to Gefitinib in a Non-small Cell Lung Cancer Patient Harboring a Rare Somatic Epidermal Growth Factor Gene Point Mutation; Codon 768 AGC > ATC in Exon 20 (S768I)Japanese Journal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 2004